Revenue + Forward P/E
Charles River Laboratories International, Inc. (CRL) quarterly revenue and forward P/EForward P/E: 23.3x
RevenueRevenue (est)Forward P/E
Fair value & valuation models
Fair value models are a Plus feature
Upgrade to Plus for the interactive DCF model, valuation bands, and implied-price scenarios.
71% OFF$23.99 $6.99/mo
Ends in23:59:59
Cancel anytime. Secure checkout via Stripe.
Valuation
Market cap
$13.72B
Enterprise value
$13.91B
P/E ratio (TTM)
-61.14x
P/S ratio (TTM)
2.74x
P/B ratio
3.82x
EV/Sales
3.45x
EV/EBITDA
47.87x
Dividend yield
0.00%
Income statement (TTM)
Revenue (TTM)
$4.02B
Gross profit (TTM)
$1.23B
Operating income (TTM)
$507.84M
EBITDA (TTM)
$410.84M
Net income (TTM)
$-144.34M
Free cash flow (TTM)
$518.49M
Margins & returns
Gross margin
31.86%
Operating margin
11.77%
Profit margin
-4.59%
Return on equity
-5.74%
Return on assets
-2.39%
Per-share metrics
EPS (TTM)
-$3.77
Dividend yield
0.00%
Beta
1.40
Capital structure
Cash & equivalents
$213.77M
Total debt
$3.07B
Net debt
$2.85B
Shares outstanding
48.17M
Financial health
Current ratio
1.29
Debt / equity
0.97
Debt / assets
0.43
Interest coverage
4.74
| Company | Market cap | P/E | P/S | EV/EBITDA | Div yield |
|---|---|---|---|---|---|
| $1.15T | 42.41x | 15.59x | 34.80x | 0.54% | |
| $629.91B | 30.45x | 6.47x | 20.76x | 1.99% | |
| $443.10B | 127.13x | 7.29x | 30.82x | 2.63% | |
| $365.06B | 27.06x | 0.85x | 16.46x | 2.13% | |
| $354.73B | 23.91x | 4.80x | 15.14x | 2.67% | |
| $332.91B | 36.82x | 4.94x | 19.57x | 2.56% | |
| $13.72B | -61.14x | 2.74x | 47.87x | - |